Bristol-Myers Squibb

Bristol-Myers Squibb

Yahoo Finance • 9 hours ago

Cytokinetics Boasts A First-Ever In Heart Disease — And Shares Drop

Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday. Continue Reading... Full story

Yahoo Finance • 15 hours ago

1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges

1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn't mean every stock is worth owning. Some companies face significant challenges, whethe... Full story

Yahoo Finance • yesterday

Uber (UBER)’s $966 Million Fine: A Temporary Headwind or Bigger Regulatory Threat?

Uber Technologies, Inc. (NYSE:UBER) is facing a major regulatory setback after the Dutch Data Protection Authority fined the company €825 million ($966 million) for using automated systems to suspend or deactivate drivers without adequate... Full story

Yahoo Finance • yesterday

NVIDIA (NVDA)’s Data Center Strategy Deepens With Cloverleaf Investment

NVIDIA Corporation (NASDAQ:NVDA) is expanding beyond chips and deeper into the infrastructure needed to run AI. The company has taken a minority stake in Cloverleaf Infrastructure, a developer that secures powered land and utility agreemen... Full story

Yahoo Finance • yesterday

New FDA Approval Gives Bristol-Myers Squibb (BMY) Another Potential Oncology Growth Catalyst

The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)'s oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma. The treatment is given with Johnson & Johnson's Darzalex an... Full story

Yahoo Finance • yesterday

RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer

Revolution Medicines RVMD announced that the FDA has approved its RAS inhibitor daraxonrasib for previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The drug will be marketed under the brand name Rasonque.... Full story

Yahoo Finance • 3 days ago

Merck Stock Hits New 52-Week High: What's Driving the Rally?

Shares of Merck MRK hit a fresh 52-week high yesterday on renewed investor confidence over the company's long-term growth prospects and recent positive developments surrounding its pipeline progress, regulatory approvals, as well as merger... Full story

Yahoo Finance • 3 days ago

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

MarketNewsUpdates.com A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where c... Full story

Yahoo Finance • 3 days ago

PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space. Oncology remains one of the most attractive and competitive areas in the pharma and biotech industry. With cancer cases cont... Full story

Yahoo Finance • 3 days ago

Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?

Immunocore's IMCR sole marketed drug, Kimmtrak (tebentafusp-tebn), which is approved for treating patients with unresectable or metastatic uveal melanoma (mUM), has been witnessing strong demand. Currently, the company's top line solely co... Full story

Yahoo Finance • 4 days ago

Eli Lilly (LLY) Is Suing Six Companies Over an Unapproved Drug—Leaving Novo Nordisk (NVO) Clear in the GLP-1 Wars

On August 12, 2026, Eli Lilly and Company (NYSE:LLY) said that it filed six lawsuits against US companies it accuses of illegally selling black-market versions of retatrutide. It is an experimental obesity drug still in Phase 3 trials and... Full story

Yahoo Finance • 4 days ago

Pfizer Stock: Wall Street Sees a Rebound, Here’s Our Price Target

Quick Read Pfizer (PFE) earns a BUY rating with a $32.36 price target, 15% upside, and a 6.19% dividend yield anchoring the rebound thesis. Pfizer trades at 10x forward earnings, a steep discount to Merck (MRK) at 18x and Bristol Myers Sq... Full story

Yahoo Finance • 4 days ago

BRC Therapeutics Appoints Biopharma Veteran Chandra Ramanathan as Executive Vice President of Commercialization and Strategy

Seasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of Growth MONTEREY, Calif., Aug. 24, 2026 /PRNewswire/ -- BRC Therap... Full story

Yahoo Finance • 5 days ago

A cancer vaccine years in the making just proved itself

On August 19, Merck (MRK) said its personalized cancer vaccine had proved effective in a large, late-stage melanoma study, and Wall Street responded fast. Merck shares closed up about 12.5% that day, one of the biggest single-day moves th... Full story

Yahoo Finance • 5 days ago

JP Morgan Warns of Fall Sell-Off Potential: 5 Defensive Dividend Stocks to Buy

Quick Read J.P. Morgan's Jason Hunter warns of autumn S&P 500 weakness, citing AI stock divergence that mirrors the 1999 to 2000 tech crash alongside rising Treasury yields. BMY yields nearly 4% with JPMorgan's recently raised $73 target,... Full story

Yahoo Finance • 7 days ago

Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK

Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it will spend about $2.3 billion on a new plant in Houston, part of a larger $40 billio... Full story

Yahoo Finance • 7 days ago

Lawmakers ask FDA to scrutinize Chinese trials amid deaths - report

[capsules showcases the flag of United State of America and China] * Two Republican congressmen are asking FDA Acting Commissioner Kyle Diamantas to place greater scrutiny on clinical trial data from China, including not accepting data... Full story

Yahoo Finance • 8 days ago

Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)

Reflecting On Branded Pharmaceuticals Stocks' Q2 Earnings: Corcept (NASDAQ:CORT) Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at Corcept (NASDAQ:CORT) and its... Full story

Yahoo Finance • 8 days ago

Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO

Quick Read SPTX's Glyph prodrug platform has generated 24 candidates, with lead asset GlyphAllo entering Phase 2b for MDD and topline results expected in 1H 2027. BMY previously paid $14 billion for Karuna Therapeutics, co-founded by Seap... Full story

Yahoo Finance • 10 days ago

Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma

Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix's role as a specialized global leader in registrational oncolo... Full story